Kyverna clinical trials target B-cell driven autoimmune diseases.
Kyverna Therapeutics is committed to developing a safe and effective autologous anti-CD19 CAR-T cell therapy for the treatment of B-cell driven autoimmune diseases. Participation in clinical trials is the best way to access our investigational product candidate.
*Inflammatory bowel disease/IBD includes Chron’s disease and ulcerative colitis programs.
Advancing the science, together
Kyverna is currently collecting treatment data from patients with lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis.
Learn more about our clinical trials and expanded access policy, and how to participate
Kyverna Therapeutics is committed to developing a safe and effective autologous anti-CD19 CAR-T cell therapy for the treatment of autoimmune diseases. Participation in clinical trials is the best way to access our investigational product.
Expanded access is the use of an investigational product outside of a clinical trial for the treatment of a serious or life-threatening condition. When participating in a clinical study is not possible, Kyverna may consider requests for expanded access in rare circumstances when an individual has no other comparable or satisfactory alternative therapy options available or is not eligible to participate in a current Kyverna clinical trial.
Patients are encouraged to speak to their doctors about whether a clinical trial is right for them. Treating physicians can find more information on our ongoing clinical trials by visiting clinicaltrials.gov or request information about our clinical trials or expanded access for a Kyverna therapy by contacting Kyverna at clinicaltrials@kyvernatx.com. Kyverna will acknowledge inquiries as soon as possible, usually within 5 business days of receipt.
Pursuant to the 21st Century Cures Act, Kyverna may revise this policy at any time and this policy shall not serve as a guarantee of access to any specific investigational therapy by any individual.